DMAC Diamedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the business activity of developing treatments for unmet clinical need or where no therapies are available with the focus on neurological and kidney diseases.

As of 09/16/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  Canada
IPO date:  12/07/2018
Outstanding shares:  18,786,157
Average volume:  234,897
Market cap:   $72,702,428
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    25253X207
ISIN:        CA25253X2077
Sedol:      BGT0PL8
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.55
PS ratio:   0.00
Return on equity:   -70.33%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy